272 related articles for article (PubMed ID: 30873933)
1. Surface Structures of Group B
Paoletti LC; Kasper DL
Microbiol Spectr; 2019 Mar; 7(2):. PubMed ID: 30873933
[TBL] [Abstract][Full Text] [Related]
2. Anti-Group B Streptococcus Glycan-Conjugate Vaccines Using Pilus Protein GBS80 As Carrier and Antigen: Comparing Lysine and Tyrosine-directed Conjugation.
Nilo A; Morelli L; Passalacqua I; Brogioni B; Allan M; Carboni F; Pezzicoli A; Zerbini F; Maione D; Fabbrini M; Romano MR; Hu QY; Margarit I; Berti F; Adamo R
ACS Chem Biol; 2015 Jul; 10(7):1737-46. PubMed ID: 25906283
[TBL] [Abstract][Full Text] [Related]
3. Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.
Yang HH; Madoff LC; Guttormsen HK; Liu YD; Paoletti LC
Infect Immun; 2007 Jul; 75(7):3455-61. PubMed ID: 17470542
[TBL] [Abstract][Full Text] [Related]
4. Temperature-Induced Self-Assembly of the Group B Streptococcus (GBS) Fusion Antigen GBS-NN.
Rose F; Roovers S; Fano M; Harloff-Helleberg S; Kirkensgaard JJK; Hejnaes K; Fischer P; Foged C
Mol Pharm; 2018 Jul; 15(7):2584-2593. PubMed ID: 29745668
[TBL] [Abstract][Full Text] [Related]
5. Glycoconjugate vaccines to prevent group B streptococcal infections.
Paoletti LC; Kasper DL
Expert Opin Biol Ther; 2003 Sep; 3(6):975-84. PubMed ID: 12943456
[TBL] [Abstract][Full Text] [Related]
6. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein.
Yang HH; Mascuch SJ; Madoff LC; Paoletti LC
Clin Vaccine Immunol; 2008 Jul; 15(7):1035-41. PubMed ID: 18463225
[TBL] [Abstract][Full Text] [Related]
7. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
[TBL] [Abstract][Full Text] [Related]
8. Development of experimental GBS vaccine for mucosal immunization.
Gupalova T; Leontieva G; Kramskaya T; Grabovskaya K; Bormotova E; Korjevski D; Suvorov A
PLoS One; 2018; 13(5):e0196564. PubMed ID: 29727446
[TBL] [Abstract][Full Text] [Related]
9. A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.
Hillier SL; Ferrieri P; Edwards MS; Ewell M; Ferris D; Fine P; Carey V; Meyn L; Hoagland D; Kasper DL; Paoletti LC; Hill H; Baker CJ
Clin Infect Dis; 2019 May; 68(12):2079-2086. PubMed ID: 30281066
[TBL] [Abstract][Full Text] [Related]
10. Identification of a universal Group B streptococcus vaccine by multiple genome screen.
Maione D; Margarit I; Rinaudo CD; Masignani V; Mora M; Scarselli M; Tettelin H; Brettoni C; Iacobini ET; Rosini R; D'Agostino N; Miorin L; Buccato S; Mariani M; Galli G; Nogarotto R; Nardi-Dei V; Vegni F; Fraser C; Mancuso G; Teti G; Madoff LC; Paoletti LC; Rappuoli R; Kasper DL; Telford JL; Grandi G
Science; 2005 Jul; 309(5731):148-50. PubMed ID: 15994562
[TBL] [Abstract][Full Text] [Related]
11. An update on vaccination against group B streptococcus.
Heath PT
Expert Rev Vaccines; 2011 May; 10(5):685-94. PubMed ID: 21604988
[TBL] [Abstract][Full Text] [Related]
12. Maternal group B streptococcal immunization: capsular polysaccharide (CPS)-based vaccines and their implications on prevention.
Palmeiro JK; De Carvalho NS; Botelho AC; Fracalanzza SE; Madeira HM; Dalla-Costa LM
Vaccine; 2011 May; 29(21):3729-30. PubMed ID: 21414381
[TBL] [Abstract][Full Text] [Related]
13. Group B Streptococcus: global incidence and vaccine development.
Johri AK; Paoletti LC; Glaser P; Dua M; Sharma PK; Grandi G; Rappuoli R
Nat Rev Microbiol; 2006 Dec; 4(12):932-42. PubMed ID: 17088932
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Wessels MR; Paoletti LC; Pinel J; Kasper DL
J Infect Dis; 1995 Apr; 171(4):879-84. PubMed ID: 7706814
[TBL] [Abstract][Full Text] [Related]
15. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
[TBL] [Abstract][Full Text] [Related]
16. Capsular switching in group B Streptococcus CC17 hypervirulent clone: a future challenge for polysaccharide vaccine development.
Bellais S; Six A; Fouet A; Longo M; Dmytruk N; Glaser P; Trieu-Cuot P; Poyart C
J Infect Dis; 2012 Dec; 206(11):1745-52. PubMed ID: 23002446
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
[TBL] [Abstract][Full Text] [Related]
18. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.
Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Edwards MS; Kasper DL
J Infect Dis; 2004 Mar; 189(6):1103-12. PubMed ID: 14999615
[TBL] [Abstract][Full Text] [Related]
19. Vaccination With a Latch Peptide Provides Serotype-Independent Protection Against Group B Streptococcus Infection in Mice.
Lin SM; Jang AY; Zhi Y; Gao S; Lim S; Lim JH; Song JY; Sullam PM; Rhee JH; Seo HS
J Infect Dis; 2017 Dec; 217(1):93-102. PubMed ID: 29106586
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III.
Baker CJ; Rench MA; Fernandez M; Paoletti LC; Kasper DL; Edwards MS
J Infect Dis; 2003 Jul; 188(1):66-73. PubMed ID: 12825173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
